Adrian Kinkaid Buys 83,728 Shares of Fusion Antibodies plc (LON:FAB) Stock

Fusion Antibodies plc (LON:FAB) insider Adrian Kinkaid acquired 83,728 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were purchased at an average cost of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,373.36).

Adrian Kinkaid also recently made the following trade(s):

• On Wednesday, September 4th, Adrian Kinkaid acquired 120,000 shares of Fusion Antibodies stock. The shares were purchased at an average cost of GBX 3 ($0.04) per share, for a total transaction of £3,600 ($4,700.97).

Fusion Antibodies Stock Down 12.2 %

Shares of FAB opened at GBX 4.30 ($0.06) on Friday. The stock has a market capitalization of £4.10 million, a price-to-earnings ratio of -107.50 and a beta of 0.49. Fusion Antibodies plc has a 1 year low of GBX 2.80 ($0.04) and a 1 year high of GBX 9.50 ($0.12). The business’s 50 day simple moving average is GBX 3.64 and its 200-day simple moving average is GBX 3.52. The company has a debt-to-equity ratio of 2.40, a current ratio of 3.87 and a quick ratio of 2.36.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.